Inositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With PCOS

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Oct 2026 → Sep 2027
See other at-risk trials from Dicle University

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 2026 to Sep 2027 Show 6 more changesShow less
    • Recruitment opened
    • Study completion pushed from Jun 2027 to Sep 2027
    • Start date changed from estimate of Aug 20, 2026 to Aug 13, 2026
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 5 of 5 entries
    • Site details revised
  2. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
3,888 trials monitored
See 157 trials at risk
Polycystic ovary syndrome (PCOS) is a common endocrine disorder frequently associated with obesity, insulin resistance (IR), and metabolic dysfunction. Although lifestyle modification is recommended as first-line therapy, the optimal dietary approach for women with PCOS remains uncertain. This randomized, controlled, open-label, parallel-group trial aims to compare the effects of a Mediterranean diet (MD) and a low-carbohydrate diet (LCD), each combined with metformin, inositol, or folic acid (active control), in obese women with PCOS and IR. A total of 102 participants will be randomly assigned to one of six intervention groups and followed for two months. Anthropometric measurements, body composition, biochemical parameters, and hedonic hunger will be assessed at baseline and after the intervention. The primary outcome is the change in insulin resistance, assessed by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), from baseline to 2 months. Secondary outcomes include changes in body composition, metabolic and biochemical parameters, and hedonic hunger.
Trial Details
NCT Number NCT07770711
Lead Sponsor Dicle University
Conditions
(from sponsor)
PCOS (Polycystic Ovary Syndrome), Insulin Resistance, Obesity (BMI>30)
Related terms Insulin Resistance, Obesity, Polycystic Ovary Syndrome
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov